Octapharma Group Publishes 2017 Annual Results Reporting Revenue of €1.72 Billion and Operating Income of €349 Million
Over the last six years, the Octapharma Group has accomplished a remarkable compound annual growth rate of 15% and reports another record-breaking result for 2017, with sales of €1.72 billion – €120 million (7.5%) more than 2016’s figure (on a constant currency basis, the growth rate is 9.4%).
Gross profit in 2017 is €592 million. Operating income is €349 million. Net cash from operating activities is €353 million (20.5% of revenue). Trade receivables have remained stable despite the significant sales growth and our net inventory has increased by €57 million, to a comfortable holding of raw plasma.
Total operating expenses were €243 million, which includes significant investment in the future product portfolio: €87 million was invested in research and development (R&D) and €201 million in the extension of our production capacity and infrastructure. The significant investment made in research and infrastructure strongly positions Octapharma to fulfil the needs of more healthcare professionals and patients around the world.
To download the full Octapharma Group 2017 Annual Report visit the Octapharma Annual Report website: www.annualreport.octapharma.com
The vision of Octapharma is “Our passion drives us to provide new health solutions advancing human life”. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. Our company values are Ownership, Integrity, Leadership, Sustainability and Entrepreneurship.
In 2017, the Group achieved €1.72 billion in revenue, an operating income of €349 million and invested €287 million to ensure future prosperity. Octapharma employs around 7,700 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:
- Haematology (coagulation disorders)
- Immunotherapy (immune disorders)
- Critical care
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden.
For more information visit www.octapharma.com
Corporate Communications Manager
Office: +41 55 4512 121
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Global IBC Future Zone and IABM Future Trends Theatre to Explore the Latest Tech Shaping the Industry20.8.2018 14:18 | Tiedote
IBC2018, the world’s most influential media, entertainment and technology show, today announces the line-up for the IBC Future Zone and IABM Future Trends Theatre. Well established as part of the IBC Exhibition, from 14-18 September, the Future Zone brings together the very latest ideas, innovations and concept technologies from international industry and academia and showcases them in a single specially-curated area sitting alongside exhibition Hall 8. This year, the focus is on showing how new technologies grow from their first inception and progress through to research, development, and validation projects; right through to maturing into the ground-breaking applications and future product standards. Major industry trail-blazers presenting their visions of the future, include Japan’s NHK and BBC R&D from the UK. Both companies will demonstrate a number of technology advances, including: Web-VR applications; object-based media scenarios; pathways to 8K resolution for UHD; and Artifici
Ocean Ambassador of the Netherlands Joins Endowment for Clean Ocean’s Entrepreneur Judges Committee20.8.2018 14:07 | Tiedote
The Endowment for Clean Oceans (ECO) announced Willemijn Peeters, Ocean Ambassador of the Netherlands and the Founding Director of Searious Business has joined ECO’s Entrepreneur Committee that will vet contestants’ plans to remove macro and micro plastics from the world’s oceans. “I am working to solve the problem of what to do with the plastic once it is removed from the ocean, by helping to create a market for plastic recovered from the ocean,” said Peeters. “Just like we need to end the use of single use plastic, we need to replace the manufacture of virgin plastic and replace it with recycled plastics, and as much as possible needs to be plastic recovered from the ocean.” View source version on businesswire.com: https://www.businesswire.com/news/home/20180820005004/en/ Contact information The Endowment for Clean Oceans Daniel Perrin Daniel.Perrin@endowmentforcleanoceans.org or email@example.com
HeartSciences Showcases MyoVista® Wavelet ECG at 2018 European Society of Cardiology Congress (ESC)20.8.2018 14:00 | Tiedote
HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing and artificial intelligence, is proud to announce its participation as an exhibitor at the upcoming 2018 European Society of Cardiology Congress (ESC). The Congress will take place at Messe Munich International in Munich, Germany and will run from August 25 to August 29, 2018. HeartSciences will highlight its MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device as well as recent clinical study results published in the Journal of the American College of Cardiology (JACC) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005047/en/ MyoVista Wavelet ECG 12-Lead Cardiac Testing Device (Photo: Business Wire) The JACC article titled “Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG” presented the results from the investigator-initiated clinical study that focus
Murata Invests in MEMS Sensor Manufacturing in Finland20.8.2018 13:00 | Tiedote
Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) expands its MEMS sensor manufacturing by building a new factory in Vantaa, Finland to increase the sensor production capacity. Total value of the investment is five billion yen. With the expansion, the company estimates to create 150–200 new jobs in 2018–2019. The MEMS sensors manufactured by Murata in Finland are used in applications such as car safety systems and pacemakers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005108/en/ New factory of Murata Electronics Oy (Graphic: Business Wire) Murata, a world leading manufacturer of electronic components, is significantly increasing global production capacity, including most recently its factory located in Finland. After having recently purchased the previously leased buildings, the company will construct a new building of approximately 16,000 square meters. The new facility is scheduled to be completed b
JAPANILAISYHTIÖ INVESTOI 42 MILJOONAA EUROA SUOMEEN20.8.2018 13:00 | Tiedote
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) Maailman johtava elektroniikkakomponenttien valmistaja Murata lisää tuotantokapasiteettiaan Suomessa rakentamalla kokonaisalaltaan 16 000 neliön tehdaslaajennuksen Vantaalle. Investoinnin arvo on 42 miljoonaa euroa, ja yhtiö rekrytoi sen myötä 150–200 uutta työntekijää vuosina 2018–2019. Muratan Suomessa valmistamia MEMS-antureita käytetään esimerkiksi itseohjautuvissa autoissa ja sydämentahdistimissa. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20180820005165/fi/ New factory of Murata Electronics Oy (Graphic: Business Wire) Japanilaisen Murata-konsernin suomalaisyhtiö Murata Electronics rakentaa merkittävän tehdaslaajennuksen Vantaalle. Investoinnin arvo on 42 miljoonaa euroa. Nykyisen tuotanto- ja tuotekehitysyksikön kylkeen nousee kolmannes lisätilaa, minkä lisäksi yhtiö on ostanut itselleen nykyiset rakennukset sekä lisää tonttimaata uusille parkkipaik
Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year20.8.2018 11:00 | Tiedote
Veristat, a full service Clinical Research Organization (CRO), proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. Since its first appearance on the list in 2015, Veristat has accelerated its growth in size, geographic reach and ability to successfully guide clinical trials through the development process to regulatory approval. “Veristat’s ability to achieve this national recognition and to remain on this list for 4 consecutive years highlights our sustainability, innovation and unfaltering commitment to consistently delivering the highest quality clinical development and regulatory submission services to our clients,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “The meaningful impact that our teams provide to our clients and to lives of the patients their programs benefit is astounding. In 2018, our teams supported five regulatory submissions that were submitted to the US Food & Dru
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme